NasdaqGS:INBXBiotechs
A Look At Inhibrx Biosciences (INBX) Valuation As Investors Await Phase 2 HexAgon Webcast Results
Inhibrx Biosciences (INBX) has drawn fresh attention after scheduling a May 11 webcast to share interim Phase 2 HexAgon data on its OX40 agonist INBRX-106 in first-line head and neck cancer.
See our latest analysis for Inhibrx Biosciences.
The webcast follows a sharp 30 day share price return of about 100% and a year to date gain of nearly 66%. However, the 1 day share price return shows a 12% decline, while the 1 year total shareholder return is around 10x.
If this kind of clinical catalyst...